266 related articles for article (PubMed ID: 20961456)
1. Estimation of the burden of cardiovascular disease attributable to modifiable risk factors and cost-effectiveness analysis of preventative interventions to reduce this burden in Argentina.
Rubinstein A; Colantonio L; Bardach A; Caporale J; Martí SG; Kopitowski K; Alcaraz A; Gibbons L; Augustovski F; Pichón-Rivière A
BMC Public Health; 2010 Oct; 10():627. PubMed ID: 20961456
[TBL] [Abstract][Full Text] [Related]
2. Generalized cost-effectiveness analysis of a package of interventions to reduce cardiovascular disease in Buenos Aires, Argentina.
Rubinstein A; García Martí S; Souto A; Ferrante D; Augustovski F
Cost Eff Resour Alloc; 2009 May; 7():10. PubMed ID: 19419570
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of medical primary prevention strategies to reduce absolute risk of cardiovascular disease in Tanzania: a Markov modelling study.
Ngalesoni FN; Ruhago GM; Mori AT; Robberstad B; Norheim OF
BMC Health Serv Res; 2016 May; 16():185. PubMed ID: 27184802
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of strategies to combat cardiovascular disease, diabetes, and tobacco use in sub-Saharan Africa and South East Asia: mathematical modelling study.
Ortegón M; Lim S; Chisholm D; Mendis S
BMJ; 2012 Mar; 344():e607. PubMed ID: 22389337
[TBL] [Abstract][Full Text] [Related]
5. Comparing Strategies for Lipid Lowering in Argentina: An Analysis from the CVD Policy Model-Argentina.
Konfino J; Fernandez A; Penko J; Mason A; Martinez E; Coxson P; Heller D; Moran A; Bibbins-Domingo K; Pérez-Stable EJ; Mejía R
J Gen Intern Med; 2017 May; 32(5):524-533. PubMed ID: 27853916
[TBL] [Abstract][Full Text] [Related]
6. [Estimate of the cardiovascular disease burden attributable to modifiable risk factors in Argentina].
Rubinstein A; Colantonio L; Bardach A; Caporale J; García Martí S; Kopitowski K; Alcaraz A; Gibbons L; Augustovski F; Pichón-Rivière A
Rev Panam Salud Publica; 2010 Apr; 27(4):237-45. PubMed ID: 20512225
[TBL] [Abstract][Full Text] [Related]
7. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.
Whitfield MD; Gillett M; Holmes M; Ogden E
Public Health; 2006 Dec; 120(12):1140-8. PubMed ID: 17084425
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Four Tobacco Control Interventions in Mongolia.
Tuvdendorj A; Feenstra T; Buskens E
Nicotine Tob Res; 2023 Sep; 25(11):1719-1726. PubMed ID: 37478493
[TBL] [Abstract][Full Text] [Related]
9. A systematic review and economic evaluation of statins for the prevention of coronary events.
Ward S; Lloyd Jones M; Pandor A; Holmes M; Ara R; Ryan A; Yeo W; Payne N
Health Technol Assess; 2007 Apr; 11(14):1-160, iii-iv. PubMed ID: 17408535
[TBL] [Abstract][Full Text] [Related]
10. Estimated effect of increased diagnosis, treatment, and control of diabetes and its associated cardiovascular risk factors among low-income and middle-income countries: a microsimulation model.
Basu S; Flood D; Geldsetzer P; Theilmann M; Marcus ME; Ebert C; Mayige M; Wong-McClure R; Farzadfar F; Saeedi Moghaddam S; Agoudavi K; Norov B; Houehanou C; Andall-Brereton G; Gurung M; Brian G; Bovet P; Martins J; Atun R; Bärnighausen T; Vollmer S; Manne-Goehler J; Davies J
Lancet Glob Health; 2021 Nov; 9(11):e1539-e1552. PubMed ID: 34562369
[TBL] [Abstract][Full Text] [Related]
11. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania.
Gilson L; Mkanje R; Grosskurth H; Mosha F; Picard J; Gavyole A; Todd J; Mayaud P; Swai R; Fransen L; Mabey D; Mills A; Hayes R
Lancet; 1997 Dec 20-27; 350(9094):1805-9. PubMed ID: 9428251
[TBL] [Abstract][Full Text] [Related]
13. Cost Effectiveness of Free Access to Smoking Cessation Treatment in France Considering the Economic Burden of Smoking-Related Diseases.
Cadier B; Durand-Zaleski I; Thomas D; Chevreul K
PLoS One; 2016; 11(2):e0148750. PubMed ID: 26909802
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk.
Kohli-Lynch CN; Bellows BK; Thanassoulis G; Zhang Y; Pletcher MJ; Vittinghoff E; Pencina MJ; Kazi D; Sniderman AD; Moran AE
JAMA Cardiol; 2019 Oct; 4(10):969-977. PubMed ID: 31461121
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of a cardiovascular disease primary prevention programme in a primary health care setting. Results of the Polish part of the EUROACTION project.
Sović N; Pająk A; Jankowski P; Duenas A; Kawecka-Jaszcz K; Wolfshaut-Wolak R; Stepaniak U; Kawalec P
Kardiol Pol; 2013; 71(7):702-11. PubMed ID: 23907903
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of a government supported policy strategy to decrease sodium intake: global analysis across 183 nations.
Webb M; Fahimi S; Singh GM; Khatibzadeh S; Micha R; Powles J; Mozaffarian D
BMJ; 2017 Jan; 356():i6699. PubMed ID: 28073749
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and cost-effectiveness of interventions that cause weight loss and reduce the risk of cardiovascular disease.
Zomer E; Leach R; Trimmer C; Lobstein T; Morris S; James WP; Finer N
Diabetes Obes Metab; 2017 Jan; 19(1):118-124. PubMed ID: 27649286
[TBL] [Abstract][Full Text] [Related]
18. The global burden of ischemic stroke: findings of the GBD 2010 study.
Bennett DA; Krishnamurthi RV; Barker-Collo S; Forouzanfar MH; Naghavi M; Connor M; Lawes CM; Moran AE; Anderson LM; Roth GA; Mensah GA; Ezzati M; Murray CJ; Feigin VL;
Glob Heart; 2014 Mar; 9(1):107-12. PubMed ID: 25432120
[TBL] [Abstract][Full Text] [Related]
19. Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis.
Salomon JA; Carvalho N; Gutiérrez-Delgado C; Orozco R; Mancuso A; Hogan DR; Lee D; Murakami Y; Sridharan L; Medina-Mora ME; González-Pier E
BMJ; 2012 Mar; 344():e355. PubMed ID: 22389335
[TBL] [Abstract][Full Text] [Related]
20. [Trends of burden on ischemic heart disease and epidemiological transition of related risk factors in China, 1990-2017].
Wang CR; Meng XF; Wang CP; Liu SW
Zhonghua Liu Xing Bing Xue Za Zhi; 2020 Oct; 41(10):1703-1709. PubMed ID: 33297630
[No Abstract] [Full Text] [Related]
[Next] [New Search]
